← board
ASMB
Assembly Biosciencesdistress 8/10 · high distress / dilution risk$25.31-3%today-34% from 52w high
Infectious Disease 2
Lead: recurrent genital herpes
Revenue
$72M
Liquidity
$31M
Runway
0.8 yrs
Shares 1y
+107%
Price & events
-8.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.8%
1D
-2.1%
1W
-5.6%
1M
-10.7%
3M
-9.6%
6M
+38.1%
1Y
+66.5%
2Y
-39.7%
5Y
-65.1%
All
Overview
- Market Cap
- $402.24M
- Volume
- 4.94K
- 52 Week Range
- $17.90 – $38.50
- Total Shares
- 15.89M
- Float Shares
- 8.80M
- Short %
- 16.32%
- % Held by Insiders
- 28.42%
- % Held by Institutions
- 48.46%
- RVOL
- 0.02x
- Beta
- 1.08
Pipeline stages · 1 programs
ABI-5366
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-02-03 | Phase 1 | ABI-5366 | Recurrent Genital Herpes Simplex Type 2 | 115 | completed |
| 2026-01-19 | Phase 1 | ABI-1179 | Recurrent Genital Herpes Simplex Type 2 | 103 | completed |
| 2025-07-08 | Phase 1 | ABI-6250 | Hepatitis Delta Virus, Hepatitis D | 40 | completed |
| 2025-04-15 | Phase 1 | ABI-4334 | Chronic Hepatitis B | 20 | completed |
Catalyst news & presentations · 8
- first quarter of 2027Guided 70%trial initiationsecondaryPhase 2ABI-6250 · Initiation of Phase 2 basket study for cholestatic liver diseases.SEC 8-K
- fourth quarter of 2026Guided 70%trial initiationsecondaryPhase 2ABI-6250 · Initiation of Phase 2 clinical study for chronic HDV infection.SEC 8-K
- mid-2026trial initiationsecondaryPhase 2ABI-5366 · Company expects to initiate Phase 2 clinical studies.SEC 8-K
- fall 2025readoutPhase 1ABI-5366 · Interim Phase 1b data for ABI-5366SEC 8-K
- fall 2025readoutPhase 1ABI-5366, ABI-1179 · Interim efficacy, safety and PK dataSEC 8-K
- 2025-08-08partnershipPrivate placement agreement with Gilead Sciences for capital raise.SEC 8-K
- first half of 2025readoutPhase 1ABI-5366 · Interim Phase 1b resultsSEC 8-K
- 2025-06-25partnershipABI-4334 · Trial completion triggers Gilead opt-in point under collaborationSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-06-15MizuhoOutperform
- 2026-05-28GuggenheimBuy
- 2026-05-04HC Wainwright & Co.Buy
- 2026-04-06GuggenheimBuy
- 2026-03-26HC Wainwright & Co.Buy
- 2025-12-22HC Wainwright & Co.Buy
Competitors — recurrent genital herpes
- none identified
Recent news
- 2026-07-23Avoiding Lag: Real-Time Signals in (ASMB) Movement - Stock Traders Daily
- 2026-07-18Assembly Biosciences strengthens antiviral plat... - Pluang
- 2026-07-18Assembly Biosciences: A Gilead-Backed Antiviral Option With More Embedded Leverage Than The Market Appreciates - Seeking Alpha
- 2026-07-14Enterprise value to EBIT forward of Assembly Biosciences, Inc. – NASDAQ:ASMB - TradingView
- 2026-07-11Avoiding Lag: Real-Time Signals in (ASMB) Movement - Stock Traders Daily
- 2026-07-11Avoiding Lag: Real-Time Signals in (ASMB) Movement - Stock Traders Daily
- 2026-07-09Price to earnings forward of Assembly Biosciences, Inc. – FWB:V7B - TradingView
- 2026-07-08Enterprise value to revenue forward of Assembly Biosciences, Inc. – NASDAQ:ASMB - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.